Show simple item record

dc.contributorSpandidos Publ.es_CL
dc.contributor.authorReyes, E [Chile. Hospital de Carabineros]es_CL
dc.contributor.authorTapia, P. [Pontificia Universidad Católica de Chile]es_CL
dc.contributor.authorBadinez, L. [Chile. Fundación Arturo López Pérez]es_CL
dc.contributor.authorOrellana, N. [Chile. Hospital de Carabineros]es_CL
dc.contributor.authorFuentealba, C. [Chile. Hospital de Carabineros]es_CL
dc.contributor.authorOlivares, R. [Chile. Hospital de Carabineros]es_CL
dc.date.accessioned2018-09-07T14:11:45Z
dc.date.available2018-09-07T14:11:45Z
dc.date.issued2012es_CL
dc.identifier.citationMurray, N. P., Reyes, E., Tapia, P., Badinez, L., Orellana, N., Fuentealba, C., ... & Dueñas, R. (2012). Redefining micrometastasis in prostate cancer-a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: Implications in determining local or systemic treatment for biochemical failure after radical prostatectomy. International journal of molecular medicine, 30(4), 896-904.es_CL
dc.identifier.issnISSN 1107-3756es_CL
dc.identifier.issnESSN 1791-244Xes_CL
dc.identifier.urihttps://www.spandidos-publications.com/ijmm/30/4/896es_CL
dc.identifier.urihttps://doi.org/10.3892/ijmm.2012.1071es_CL
dc.identifier.urihttp://repositorio.umayor.cl/xmlui/handle/sibum/2768
dc.description.abstractThe presence of cells positive for cytokeratins or prostate-specific antigen (PSA) in bone marrow aspirates (BMAs) has been used to indicate the presence of micrometastasis. The aim of this prospective study of prostate cancer patients was to determine the presence of prostate cells in blood and BMAs and to compare them with bone marrow biopsy touch prep samples. The results indicated that there was a satisfactory concordance between circulating prostate cells (CPCs) in blood and disseminated tumor cells (DTCs) in BMAs for all Gleason scores (κ>0.50). However, neither were concordant with the presence of prostate cells in bone marrow biopsies except for high-grade tumors, Gleason 8 and 9. Phenotypic characteristics of CPCs and DTCs were identical (κ>0.9) but were different than cells detected in bone marrow biopsies (κ<0.2). The expression of matrix metalloproteinase-2 (MMP-2) in bone marrow biopsies was positively associated with the Gleason score (trend Chi-squared <0.05) and may explain the differences between the presence of DTCs and the presence of prostate cells in bone marrow biopsies. If the presence of DTCs was used to indicate micrometastatic disease, 20% of patients would be misclassified compared to micrometastasis defined as patients with a positive biopsy. This may have clinical implications for patients with low-grade tumors.es_CL
dc.description.sponsorshipEste trabajo no contó con financiamiento.es_CL
dc.format.extentARTÍCULO ORIGINALes_CL
dc.language.isoenes_CL
dc.publisherCIENCIASes_CL
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chilees_CL
dc.subjectONCOLOGÍAes_CL
dc.titleRedefining micrometastasis in prostate cancer - a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: Implications in determining local or systemic treatment for biochemical failure after radical prostatectomyes_CL
dc.typeArtículo o Paperes_CL
umayor.indizadorCOTes_CL
umayor.politicas.sherpa/romeoLicencia color: BLANCO (El archivo no está formalmente admitido)--Pre-print del autor: el autor no puede archivar la versión pre-print (ie la versión previa a la revisión por pares) Post-print del autor: el autor no puede archivar la versión post-print (ie la versión final posterior a la revisión por pares) Versión de editor/PDF: el autor puede archivar la versión PDF de la editorial siempre que se cumplan las restricciones: 6 meses de embargo Condiciones generales: La versión de editor/PDF debe utilizarse, On Institutional Repository or Funder's repository, Debe ir enlazado a la versión de editor, La fuente publicada debe reconocerse con la cita completa, Publisher will automatically deposit authors post-print in PubMed Central or Europe PMC after 6 months or 12 months as required by funding agency// Disponible en: http://www.sherpa.ac.uk/romeo/issn/1107-3756/es/es_CL
umayor.indexadoWOSes_CL
dc.identifier.doi10.3892/ijmm.2012.1071es_CL]
umayor.indicadores.wos-(cuartil)Q2es_CL
umayor.indicadores.scopus-(scimago-sjr)sin informaciónes_CL


Show simple item record